Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $18,120.30 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,553 shares of the stock in a transaction dated Tuesday, October 27th. The shares were acquired at an average cost of $5.10 per share, for a total transaction of $18,120.30. Following the completion of the acquisition, the insider directly owned 733,270 shares of the company’s stock, valued at approximately $3,739,677. This trade represents a 0.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The shares were bought at an average cost of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock. The shares were bought at an average cost of $4.83 per share, for a total transaction of $27,173.58.
• On Friday, July 31st, Adar1 Capital Management, Llc purchased 36,303 shares of NextCure stock. The stock was bought at an average price of $4.94 per share, for a total transaction of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc acquired 292,850 shares of NextCure stock. The shares were purchased at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc acquired 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00.

NextCure Stock Performance

Shares of NXTC opened at $6.53 on Friday. NextCure, Inc. has a 52-week low of $1.55 and a 52-week high of $15.74. The business’s fifty day moving average is $6.10 and its 200-day moving average is $7.92. The firm has a market cap of $23.57 million, a price-to-earnings ratio of -0.75 and a beta of 1.33.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Institutional Trading of NextCure

A hedge fund recently raised its stake in NextCure stock. Renaissance Technologies LLC lifted its holdings in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the period. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 at the end of the most recent reporting period. 42.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NXTC has been the subject of several research reports. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Finally, Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, NextCure has a consensus rating of “Hold” and a consensus target price of $19.00.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.